Navigation Links
ProMIS Neurosciences Declares PMN 310 its First Lead Product for Development in Alzheimer’s Disease
Date:1/6/2017

ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that PMN 310, a monoclonal antibody (mAb), has been designated its first lead product for development in Alzheimer’s disease (AD).

“We previously demonstrated that the mAb therapeutic candidates ProMIS is developing display the optimal target profile of selectively binding prion-like forms of Aß and inhibiting both their propagation (spreading) and neurotoxicity in laboratory tests (in vitro),” stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “We have now achieved a significant development milestone by demonstrating that PMN 310 directly blocks the neurotoxicity of these prion-like forms of (Aß) in a well validated mouse model.”

The neuroprotective effect of PMN 310 was investigated at a well recognized contract research organization (CRO) specializing in neurodegenerative diseases. Injection of prion-like forms of Aß (also called toxic oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called novel object recognition. Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, oligomer-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN310 to mice completely prevented the loss of short-term memory formation caused by toxic oligomers.

“The past year has been devoted to characterizing our mAbs with a view to select and prioritize our therapeutic candidates for AD; these compelling in vivo results have led us to declare PMN 310 our first lead product for development in AD,” commented Eugene Williams, ProMIS Executive Chairman. “Furthermore, the animal model used is particularly relevant to recent scientific developments that toxic prion-like forms of Aß are the appropriate target for therapy, and to our knowledge, PMN 310 is the first mAb specifically designed to address this target.”

About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences aims to develop novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
http://www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

NATIONAL Equicom
Michael Moore             
Tel. 858-886-7813         
mmoore(at)national(dot)ca

Abby Garfunkel
Tel. 403-218-2887
Tel. 403-218-2887

or contact

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences(dot)com

Read the full story at http://www.prweb.com/releases/2017/01/prweb13959568.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. University Of Colorado Cancer Center Tests Promising New Drug to Treat and Protect Against Radiotherapy-Associated Oral Mucositis
2. Scientists Find Way to Fast-Track Production of Stem Cells that Show Promise in Treating AMD
3. BioRestorative Therapies Announces the Development of an Extract that has Promise for Use in Beauty Care Products
4. AB 1000 Clears California Assembly Floor and Cited as Historic Compromise
5. All New Laguna Beach Meeting Packaging at the Aliso Creek Inn & Golf Course Promises to Take the Hassle Out of Planning the Company's Next Business Meeting
6. Elsevier and Australasian Research Management Society Honor Promising Young Scientists for their Work in Academic Research
7. 2013 Neurotech Leaders Forum to Feature Promising New Startups
8. Atomically thin device promises new class of electronics
9. Copper promises cheaper, sturdier fuel cells
10. Process holds promise for production of synthetic gasoline
11. New study explains why promising dementia drugs failed in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... 16, 2017 , ... Cynvenio Biosystems, Inc. a ... Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known ... and accurately identify tumor-related genetic mutations that can be treated with targeted therapies. ...
(Date:5/16/2017)... Cleveleys (UK) , ... (PRWEB) ... ... 10th Annual Congress of the Chinese Association of Orthopaedic Surgeons (CAOS), long-standing ... ("Double Medical") collaborated on an interbody spine surgery workshop to help expand ...
(Date:5/15/2017)... ... May 15, 2017 , ... Tunnell Consulting announced that Julia ... Key Role of Specifications in Process Validation,” at the Process Validation Summit 2017, ... bring together leaders from the pharmaceutical and biotech industries to explore processes, strategies and ...
(Date:5/15/2017)... ... May 15, 2017 , ... Algenist is continuing to disrupt ... gravity-shattering cream with a patented formula, clinically proven to deliver visible firming results ... Contouring Cream to our already innovative ELEVATE product line,” said vice president of ...
Breaking Biology Technology:
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... MONICA, Calif. , April 13, 2017 ... New York will feature emerging and evolving ... Summits. Both Innovation Summits will run alongside the expo ... of speaker sessions, panels and demonstrations focused on trending ... coast,s largest advanced design and manufacturing event will take ...
Breaking Biology News(10 mins):